April 29, 2025 – Abeona Therapeutics Inc., a prominent biopharmaceutical company that develops cell and gene therapies for serious diseases, received U.S. Food and Drug Administration (FDA) approval for ZEVASKYN. With this announcement, ZEVASKYN becomes the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with RDEB (recessive d... https://www.coherentmarketinsights.com/news/us-fda-approves-first-and-only-cell-based-gene-therapy-for-rare-genetic-skin-disorder-1239